Product Notification on Desferrioxamine Mesylate for Injection BP 500mg Freeze-Dried [Hospira]

Hospira Singapore would like to notify healthcare professionals of a potential quality problem associated with Desferrioxamine Mesylate for Injection BP 500mg Freeze-dried. Hospira to date has received 26 complaints regarding the formation of fine precipitates after reconstitution of Desferrioxamine Mesylate for Injection BP 500mg since September 2008. None of the complaints were associated with adverse drug reactions.The formation of fine precipitates occurred either in the vial or after the reconstituted solution had been injected into the infusion device usually after 24 to 48 hours of storage, and within 24 hours in some cases. Hospira is conducting investigations into the cause of the precipitates in the desferrioxamine injection. Healthcare professionals are in the meantime, advised to adhere to the reconstitution guidelines provided in the letter and report adverse drug reactions suspected to be associated with the product to HSA.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.